People
Three biotech firms announced a change in leadership recently, led by Pardes Biosciences, followed by HUTCHMED and BeiGene. Read the details below.
The Phase I study could potentially result in RP-A501 becoming the first gene therapy for monogenic heart failure.
Robert Califf became the new commissioner of the U.S. Food & Drug Administration and emphasized the use of real-world evidence (RWE) in Agency decisions.
With all of this innovation coming down the pike, Gallant shared that Daiichi Sankyo is currently in growth mode, particularly when it comes to oncology.
Six months into the job, Chief Executive Officer Deepa Prasad left vTv Therapeutics. Not long ago, the former CEO dramatically slashed its workforce to ensure funding for its lead diabetes asset.
Members of the Sackler family will dedicate at least $5.5 billion plus 100% of the debtors’ assets to opioid abatement and victims.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Foresite Labs CEO Vikram Bajaj believes that data science will fundamentally transform the life sciences and translate into the development of new therapeutics for various disease states.
Healx brings the power of artifical intelligence (AI) to rare disease research with an ultimate focus on improving patient outcomes.
On Wednesday, Massachusetts-based ConforMIS said it was suspending all distribution of its orthopedic medical devices to Russia and any Russian-based entities.
PRESS RELEASES